AU Patent

AU2017211540B2 — Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer

Assigned to Pfizer Inc · Expires 2020-04-30 · 6y expired

What this patent protects

The present disclosure describes combination therapies comprising an agonist of OX40 and an agonist of 4-1BB, and the use of the combination therapies for the treatment of cancer.

USPTO Abstract

The present disclosure describes combination therapies comprising an agonist of OX40 and an agonist of 4-1BB, and the use of the combination therapies for the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017211540B2
Jurisdiction
AU
Classification
—
Expires
2020-04-30
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.